TY  - JOUR
AU  - Bjekić-Macut, Jelica
AU  - Vukašin, Tamara
AU  - Velija-Ašimi, Zelija
AU  - Bureković, Azra
AU  - Zdravković, Marija
AU  - Andrić, Zoran
AU  - Branković, Marija
AU  - Crevar-Marinović, Slobodanka
AU  - Mandić, Tatjana
AU  - Stanojlović, Olivera
AU  - Vojnović-Milutinović, Danijela
AU  - Livadas, Sarantis
AU  - Mastorakos, George
PY  - 2021
UR  - https://radar.ibiss.bg.ac.rs/handle/123456789/4307
AB  - Polycystic ovary syndrome (PCOS) is a frequent endocrine disease in women during reproductive period. It is considered a complex metabolic disorder with long-term metabolic, as well as reproductive consequences. Main pathophysiological pathways are related to the increased androgen levels and insulin resistance. Nowadays, genetic origins of PCOS are acknowledged, with numerous genes involved in the pathogenesis of hyperandrogenemia, insulin resistance, inflammation and disturbed folliculogenesis. Rotterdam diagnostic criteria are most widely accepted and four PCOS phenotypes have been recognized. Metabolic abnormalities are more common in phenotypes 1 and 2. Women with classic PCOS are more obese and typically have central type of obesity, more prevalently displaying dyslipidemia, insulin resistance and metabolic syndrome that could be associated with an increased risk of cardiovascular complications during life. Heterogeneity of phenotypes demands an individualized approach in the treatment of women with PCOS. Metabolic therapies involve a lifestyle intervention followed by the introduction of insulin sensitizers including metformin and inositols, glucagon-like peptide 1 receptor agonists (GLP-1 RA), as recently sodium glucose contransporter-2 (SGLT2) inhibitors. Addition of an insulin sensitizer to the standard infertility therapy such as CC improves ovulation and pregnancy rates. Our current review analyzes the contemporary knowledge of PCOS etiology and etiopathogenesis, its cardiometabolic risks and their outcomes, as well as therapeutic advances for women with PCOS.
PB  - Bentham Science Publishers
T2  - Current Pharmaceutical Design
T1  - Polycystic Ovary Syndrome: A Contemporary Clinical Approach
VL  - 27
DO  - 10.2174/1381612827666210119104721
SP  - 1
EP  - 9
ER  - 

@article{
author = "Bjekić-Macut, Jelica and Vukašin, Tamara and Velija-Ašimi, Zelija and Bureković, Azra and Zdravković, Marija and Andrić, Zoran and Branković, Marija and Crevar-Marinović, Slobodanka and Mandić, Tatjana and Stanojlović, Olivera and Vojnović-Milutinović, Danijela and Livadas, Sarantis and Mastorakos, George",
year = "2021",
abstract = "Polycystic ovary syndrome (PCOS) is a frequent endocrine disease in women during reproductive period. It is considered a complex metabolic disorder with long-term metabolic, as well as reproductive consequences. Main pathophysiological pathways are related to the increased androgen levels and insulin resistance. Nowadays, genetic origins of PCOS are acknowledged, with numerous genes involved in the pathogenesis of hyperandrogenemia, insulin resistance, inflammation and disturbed folliculogenesis. Rotterdam diagnostic criteria are most widely accepted and four PCOS phenotypes have been recognized. Metabolic abnormalities are more common in phenotypes 1 and 2. Women with classic PCOS are more obese and typically have central type of obesity, more prevalently displaying dyslipidemia, insulin resistance and metabolic syndrome that could be associated with an increased risk of cardiovascular complications during life. Heterogeneity of phenotypes demands an individualized approach in the treatment of women with PCOS. Metabolic therapies involve a lifestyle intervention followed by the introduction of insulin sensitizers including metformin and inositols, glucagon-like peptide 1 receptor agonists (GLP-1 RA), as recently sodium glucose contransporter-2 (SGLT2) inhibitors. Addition of an insulin sensitizer to the standard infertility therapy such as CC improves ovulation and pregnancy rates. Our current review analyzes the contemporary knowledge of PCOS etiology and etiopathogenesis, its cardiometabolic risks and their outcomes, as well as therapeutic advances for women with PCOS.",
publisher = "Bentham Science Publishers",
journal = "Current Pharmaceutical Design",
title = "Polycystic Ovary Syndrome: A Contemporary Clinical Approach",
volume = "27",
doi = "10.2174/1381612827666210119104721",
pages = "1-9"
}

Bjekić-Macut, J., Vukašin, T., Velija-Ašimi, Z., Bureković, A., Zdravković, M., Andrić, Z., Branković, M., Crevar-Marinović, S., Mandić, T., Stanojlović, O., Vojnović-Milutinović, D., Livadas, S.,& Mastorakos, G.. (2021). Polycystic Ovary Syndrome: A Contemporary Clinical Approach. in Current Pharmaceutical Design
Bentham Science Publishers., 27, 1-9.
https://doi.org/10.2174/1381612827666210119104721

Bjekić-Macut J, Vukašin T, Velija-Ašimi Z, Bureković A, Zdravković M, Andrić Z, Branković M, Crevar-Marinović S, Mandić T, Stanojlović O, Vojnović-Milutinović D, Livadas S, Mastorakos G. Polycystic Ovary Syndrome: A Contemporary Clinical Approach. in Current Pharmaceutical Design. 2021;27:1-9.
doi:10.2174/1381612827666210119104721 .

Bjekić-Macut, Jelica, Vukašin, Tamara, Velija-Ašimi, Zelija, Bureković, Azra, Zdravković, Marija, Andrić, Zoran, Branković, Marija, Crevar-Marinović, Slobodanka, Mandić, Tatjana, Stanojlović, Olivera, Vojnović-Milutinović, Danijela, Livadas, Sarantis, Mastorakos, George, "Polycystic Ovary Syndrome: A Contemporary Clinical Approach" in Current Pharmaceutical Design, 27 (2021):1-9,
https://doi.org/10.2174/1381612827666210119104721 . .